Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. Aug. 30, 2018. Scott Whitaker.

Executive Summary

AdvaMed CEO Scott Whitaker isn't happy about new Netflix documentary "The Bleeding Edge," which is highly critical of the medical device industry and US FDA. See what Whitaker – who was featured in the film – said about it here.

"I've been in this town a long time [and] I don't believe serious policymakers are going to look at a film like this and make policy and regulatory judgments based on what they said. Because people in this town are smart enough to know that it was an entertainment piece, that it was not fact-based, that it distorted quotes that not only I made but others made, and as a result of that it's not a basis for changing the regulatory process, that by and large has worked very, very well." –Scott Whitaker, CEO, AdvaMed

Click here for a free trial of Medtech Insight

 
Advertisement

Related Content

Top Medtech Lobbyist Doubts Legislative Repercussions Of New Netflix Documentary

Topics

Advertisement
UsernamePublicRestriction

Register

MT123197

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel